Joint (JYNT) Expected to Announce Earnings on Thursday

Joint (NASDAQ:JYNT) is anticipated to issue its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect Joint to post earnings of $0.05 per share and revenue of $14.1170 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

Joint Stock Performance

Shares of JYNT stock opened at $8.48 on Tuesday. Joint has a fifty-two week low of $7.50 and a fifty-two week high of $13.47. The firm has a market capitalization of $126.10 million, a price-to-earnings ratio of -141.31 and a beta of 1.33. The stock’s 50-day simple moving average is $9.29 and its 200-day simple moving average is $9.13.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Joint in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Joint has an average rating of “Hold” and a consensus target price of $17.00.

Insider Buying and Selling at Joint

In other news, major shareholder Charles E. Jobson bought 16,753 shares of the stock in a transaction dated Friday, January 23rd. The shares were acquired at an average cost of $10.00 per share, with a total value of $167,530.00. Following the purchase, the insider directly owned 1,638,424 shares in the company, valued at $16,384,240. The trade was a 1.03% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have bought a total of 37,849 shares of company stock valued at $348,981 in the last three months. Corporate insiders own 27.90% of the company’s stock.

Hedge Funds Weigh In On Joint

Several institutional investors and hedge funds have recently modified their holdings of JYNT. XTX Topco Ltd acquired a new position in Joint in the 4th quarter worth about $124,000. Price T Rowe Associates Inc. MD boosted its position in Joint by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 26,504 shares of the company’s stock worth $232,000 after purchasing an additional 5,800 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Joint by 77.3% in the fourth quarter. Russell Investments Group Ltd. now owns 205,411 shares of the company’s stock valued at $1,791,000 after purchasing an additional 89,526 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Joint in the fourth quarter valued at approximately $766,000. Finally, Barclays PLC increased its position in shares of Joint by 5.3% in the fourth quarter. Barclays PLC now owns 32,235 shares of the company’s stock valued at $281,000 after buying an additional 1,623 shares in the last quarter. Hedge funds and other institutional investors own 76.88% of the company’s stock.

Joint Company Profile

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.